1	Clinical validity of single-gene non-invasive prenatal testing for sickle cell
2	disease and beta thalassemia
3	List of authors:
4	Erik R. WESTIN PhD <sup>1</sup> , David S. TSAO PhD <sup>2</sup> , Oguzhan ATAY PhD <sup>2</sup> , Brian P. LANDRY PhD <sup>2</sup> ,
5	Patrick P. YE PhD <sup>2</sup> , Devon CHANDLER-BROWN PhD <sup>2</sup> , Brian ALFORD PhD <sup>2</sup> , Jennifer
6	HOSKOVEC GCG <sup>2</sup> , Akila SUBRAMANIAM MD, MPH <sup>3</sup> , Kevin M. PAWLIK PhD <sup>4</sup> , Spencer
7	G. KUPER MD <sup>5</sup> , Frederick D. GOLDMAN MD <sup>6</sup> , Tim M. TOWNES PhD <sup>4</sup> *, Vivien A.
8	SHEEHAN MD PhD <sup>7</sup> *
9	<sup>1</sup> Department of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294
10	<sup>2</sup> BillionToOne, Inc, Menlo Park, CA 94025
11	<sup>3</sup> Center for Women's Reproductive Health, Department of Obstetrics and Gynecology,
12	University of Alabama at Birmingham, Birmingham, AL 35294
13	<sup>4</sup> Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham,
14	Birmingham, AL 35294
15	<sup>5</sup> Tri-State Perinatology, Deaconess – The Women's Hospital, Newburgh, IN 47630
16	<sup>6</sup> Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35294
17	<sup>7</sup> Department of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine,
18	Houston, TX 77030
19	*These authors contributed equally
20	Disclosure Statement:
21	DST, OA, BL, PPY, DCB, BA and JH are employees of BillionToOne and hold stock or options
22	to hold stock in the company. VAS received a grant from BillionToOne directly and as a
23	subcontractor from NIH. ERW, AS, KAP, SGJ, FDG, and TMT report no conflict of interest.

-	
-	

## 24 Source of Financial Support:

- 25 Research reported in this publication was supported by the National Heart, Lung, and Blood
- 26 Institute (BillionToOne, R43HL144322) and by the National Institute of Diabetes and Digestive
- and Kidney Diseases (VAS, 1K08DK110448-01). Funding was also provided by BillionToOne,
- Inc. The content is solely the responsibility of the authors and does not necessarily represent the
- 29 official views of the National Institutes of Health.

30

#### 31 Corresponding Authors:

32 Erik R. Westin PhD westine@uab.edu

33

#### 34 Condensation:

35 This study assessed and confirmed in a blinded, retrospective clinical study at two academic

36 medical centers the clinical validity of a single-gene non-invasive prenatal testing method for

37 sickle cell disease and  $\beta$ -thalassemia.

38 Short Title:

39 Clinical validity of sgNIPT for hemoglobinopathies

#### 3

# 41 AJOG at a Glance:

42	A.	Why was this study conducted?
43		Effective non-invasive prenatal testing (NIPT) is needed to permit safe in utero diagnosis
44		of sickle cell disease (SCD) and beta thalassemia ( $\beta$ -thalassemia), and permit collection and
45		banking of cord blood for future cell therapy. We have previously developed a single-gene
46		NIPT method for SCD and $\beta$ -thalassemia, with extensive analytic validation and initial
47		clinical validation in our prior studies.
48		
49	B.	What are the key findings?
50		Our single-gene NIPT detection of SCD and $\beta$ -thalassemia disease was 100% concordant
51		with newborn screening follow-up data in 79 pregnancies at risk for beta
52		hemoglobinopathies. Furthermore, a more stringent requirement, the detection of exact
53		fetal genotype, was concordant in 67 out of 68 (98.5%) of pregnancies.
54		
55	C.	What does this study add to what is already known?
56		Our results validated that single-gene NIPT is an accurate and significantly improved screen
57		for prenatal detection of SCD and $\beta$ -thalassemia compared to current carrier screen
58		workflow.

#### 60 Abstract

Background: Sickle cell disease (SCD) and beta thalassemia (β-thalassemia) are among the most 61 common and severe genetically inherited disorders in the world. Although the maternal carrier 62 status of these beta hemoglobinopathies is screened as a part of routine prenatal care in the US, the 63 paternal carrier status is usually unavailable. Under this current screening paradigm, identification 64 of the majority of SCD and beta thalassemia cases could therefore be delayed until newborn 65 screening results are available. An effective reflex, non-invasive prenatal test (NIPT) that uses 66 67 only maternal blood would permit prenatal detection of sickle cell disease and beta thalassemia by screening for these disorders without the need for paternal DNA. This screening would enable 68 patients and healthcare providers to make informed decisions about diagnostic testing, and it could 69 expand gene therapy treatment options by requesting cord blood banking at delivery. We have 70 previously developed a single-gene NIPT platform (UNITY<sup>TM</sup>) for SCD and beta thalassemia with 71 72 extensive analytic validation and initial clinical validation in our prior studies.

Objectives: The objective of this study is to further assess the clinical validity of single-gene NIPT
for SCD and beta thalassemia in a larger pregnancy population.

75 Study Design: Pregnant women who screened positive for at least one allele of a beta hemoglobinopathy were enrolled at two academic medical centers for this retrospective cohort 76 77 study. Single-gene NIPT for SCD and beta thalassemia was performed in blinded fashion on maternal blood samples to determine the fetal genotype and disease status. Single-gene NIPT 78 79 findings were compared with either newborn screen results or genotyping of umbilical cord blood. Results: Single-gene NIPT detection of fetuses that are affected versus unaffected with SCD and 80 beta thalassemia was 100% concordant with newborn screening follow-up data, even in 81 82 challenging samples that contained a low fetal fraction (<5%) or at earlier gestational ages.

5

Additionally, we obtained 98.5% concordance with newborn genotypes, including differentiating
healthy fetal sickle cell carriers from homozygous healthy fetuses. The sensitivity of detecting fetal
carrier status of beta hemoglobinopathies was 100% (90.8% to 100% CI), and the specificity was
96.4% (81.7% to 99.9 % CI). **Conclusions:** Single-gene NIPT is a highly accurate screen for prenatal detection of SCD and beta

87 Conclusions: Single-gene NIPT is a highly accurate screen for prenatal detection of SCD and beta
88 thalassemia. The results further suggest that the maternal carrier screen with reflex single-gene

NIPT workflow can significantly improve the detection rates of at-risk pregnancies from <50%

90 to >98%.

## 91 Key Words/Phrases

92 Hemoglobinopathy, sickle cell disease, beta thalassemia, recessive,  $\beta$ -globin, *HBB*, cell-free fetal

93 DNA, prenatal screening, non-invasive prenatal diagnostics, Quantitative Counting Template

## 94 Introduction:

Hemoglobinopathies are the most common genetic disorders in the world.<sup>1</sup> Beta 95 hemoglobinopathies, including sickle cell disease (SCD) and beta thalassemia ( $\beta$ -thalassemia), are 96 recessively inherited genetic disorders caused by mutations in the  $\beta$ -globin gene, and are often 97 debilitating disorders that require lifelong management. SCD is the most common monogenic 98 disorder with high prevalence among individuals originating from Sub-Saharan Africa, Middle 99 East, South Asia, and the Mediterranean.<sup>2</sup> In the United States, about 1.5% of newborns screen 100 101 positive for a beta hemoglobinopathy, and over 100,000 people have SCD<sup>3</sup>. Among African Americans, about 1 in 12 are carriers and 1 in 365 are affected with SCD.<sup>2,4</sup> Limited diversity 102 exists among pathogenic variants related to SCD including the most common mutation, Glu6Val 103 (HbS), and less common variants such as Glu6Lys (HbC), Glu26Lys (HbE).<sup>5</sup> Mutations found in 104  $\beta$ -thalassemia are much more diverse (>200) and range from a reduction in beta globin chains 105 (beta<sup>+</sup>) to mutations that lead to an absence of beta globin production (beta<sup>0</sup>).<sup>6</sup> Compound 106 heterozygosity of SCD and β-thalassemia variants is rare and prognoses differ depending on the 107 underlying genotype. 108

Current medical guidelines, including ACOG Committee Opinion 691, recommend that all 109 pregnancies should be carrier screened for these recessively inherited hemoglobinopathies.<sup>7</sup> 110 Screening is important for a number of reasons, including allowing parents to make informed 111 choices, early genetic counseling, as well as optimal *in utero* and postpartum care. Additionally, 112 prenatal testing is essential to identify fetuses for whom cord blood could be banked for future 113 treatments. One example is gene based therapy using autologous hematopoietic stem cells (HSCs), 114 115 an emergent therapeutic approach that can overcome the limitations of allogenic cell transplantation, one of which is limited donor availability.<sup>8–12</sup> The first stem cell treatment for  $\beta$ -116

7

thalassemia has already been approved in Europe and a number of Phase I, II, and III clinical trials are underway using lentiviral or CRISPR-editing methods to treat sickle cell disease and beta thalassemia. These trials suggest that stem cell-based treatments are only a few years away from clinical use making identification of fetuses affected by hemoglobinopathies paramount, so that cord blood, as a key source of stem cells, can be banked.

However, the traditional carrier screening workflow has relatively low sensitivity for 122 detecting high-risk fetuses due to problems associated with paternal testing.<sup>13</sup> Importantly, a 123 review of all prenatal and preconception patients seen for genetic counseling by the University of 124 Texas Health Genetic Counseling groups found that among all women who received an abnormal 125 carrier screening result, only 41.5% of their male partners completed screening.<sup>14</sup> This suggests 126 that at least 58.5% of affected fetuses can be missed by the current carrier screening workflow. 127 Even if a positive paternal carrier status is obtained, the risk that the fetus is affected is at most 1 128 in 4. This can be an unsatisfying prior risk for patients, genetic counselors, and healthcare providers 129 130 as they decide whether to obtain better information about the fetal disease status by invasive tests such as amniocentesis or chorionic villus sampling. 131

132 Therefore, there is an important unmet need for effective and accurate prenatal screening 133 for recessive genetic disorders that does not require paternal DNA. NIPT, which analyzes cell-free fetal DNA circulating in maternal blood, has recently become standard of care for genetic 134 aneuploidies.<sup>15</sup> However, current clinical cell-free DNA (cfDNA)-based prenatal tests are limited 135 to the detection of chromosomal abnormalities or large structural variants.<sup>15</sup> Limitations of existing 136 NIPT approaches, including the inability of these aneuploidy methods to accurately count the 137 number of input DNA molecules, have prevented application of NIPT in hemoglobinopathies and 138 other recessive single-gene disorders. In research contexts, digital droplet PCR-based NIPTs have 139

8

been developed for monogenic, recessively inherited disorders.<sup>16,17</sup> However, these tests require
knowing the maternal and paternal pathogenic variants in order to design a personalized assay for
each case. Furthermore, the personalized assay design can result in longer turn-around times and
limited clinical laboratory throughput. To overcome these limitations, we previously developed a
sequencing-based single-gene NIPT platform (UNITY<sup>TM</sup>), which uses Quantitative Counting
Template (QCT) molecules to simultaneously detect all common pathogenic variants for beta
hemoglobinopathies in cfDNA.<sup>18</sup>

The objective of this study is to further assess the clinical validity of UNITY for detecting fetal beta hemoglobinopathy status (e.g. carrier or affected) in a pregnant cohort. We have previously validated this approach analytically and clinically in smaller cohorts.<sup>18</sup> To further validate the utility of single-gene NIPT for SCD and beta thalassemia, herein we performed singlegene NIPT on maternal plasma obtained from a retrospective cohort of pregnant women identified as healthy carriers for SCD or beta thalassemia, or individuals affected by SCD after 10 weeks gestation, and compared the results with newborn follow-up data.

154

#### **Materials and Methods:**

This clinical study included pregnant women who had previously screened positive for beta
hemoglobinopathy carrier status. Samples were collected from 79 subjects between October
2018 and December 2019 at the Baylor College of Medicine and University of Alabama at
Birmingham with informed consent under protocols approved by institution's internal review
boards. Samples were shipped to BillionToOne's laboratory for processing and NIPT
bioinformatic analysis, with operators blinded to the fetal/newborn disease status. Ground truth
outcomes were determined after birth either by chart review of state newborn screening results or

9

163 by genotyping of umbilical cord blood. Study exclusion criteria were multiple gestation,

unavailability of newborn ground truth, and assay failure (e.g., contamination or sequencing

165 quality control failure).

166 Sample collection, processing and NIPT analysis

Venous blood samples were collected in Streck cell-free DNA blood collection tubes, 167 shipped to BillionToOne's centralized laboratory, and processed for single-gene NIPT. Cell-free 168 DNA was purified from maternal plasma, with 10 ul used to determine the fetal fraction and the 169 remaining 35 µl of cfDNA was used for the allele fraction (AF) assay. The AF assay determines 170 the likelihood ratio (LR) of fetal disease status based on measured diseased AF, fetal fraction, and 171 genomic equivalents (GEs) in a relative mutation dosage (RMD) analysis.<sup>18</sup> DNA purification, 172 173 library preparation, bioinformatics processing, and assessing disease risk via NIPT statistical modeling were carried out as previously described.<sup>18</sup> 174

Since the paternal carrier status is unknown in these samples, an upper bound for pre-test 175 176 and post-test probability of disease was calculated based on the ethnic population with the highest variant frequencies. When the mother is an unaffected carrier, the pre-test probability of fetal beta 177 178 hemoglobinopathy is one fourth of the paternal carrier frequency rate. In the US, African 179 Americans have the highest population allele frequency for beta hemoglobinopathy variants (1 in 12).<sup>2</sup> Within the African American population, the highest subpopulation allele frequency is 1 in 180 8.<sup>19</sup> The upper bound of pre-test probability of single-gene NIPT in this study is thus 1 in 32. The 181 post-test probability is calculated from the pre-test probability and the likelihood ratio (LR) 182 obtained from RMD analysis.<sup>20</sup> 183

The *HBB* genotypes (i.e., sickle cell carrier status) of unaffected fetuses were called based
solely on a LR score without factoring in pre-test probabilities. Pre-test probabilities are less

10

important for determining the fetus's carrier status, since the probabilities of the fetus being a carrier versus inheriting two benign alleles are approximately equal. The likelihood ratio was calculated through RMD analysis of the benign allele, comparing the likelihood of inheriting two copies of the benign allele versus single-copy inheritance based on the allele dosage.

190

#### 191 Ground truth collection from umbilical cord blood

The disease status of the fetus was obtained after the child was born and underwent either universal newborn screening (NBS) or genetic analysis of umbilical cord blood. Cord blood was collected in a cord blood collection unit (Pall) via umbilical cord venipuncture. One to five microliters were removed from the collection bag under sterile conditions and lysed. Genotype was determined by the presence/absence of variant beta globin proteins in lysis solution via a lateral flow chromatographic immunological assay using HemotypeSC (Silver Lake Research) or Sickle SCAN (Biomedomics). Genotype testing was limited to HbA, HbS and HbC variants.

**199** Statistical analysis

200 Online statistics calculator MedCalc (https://www.medcalc.org/calc/diagnostic\_test.php) 201 was used to calculate specificity and sensitivity of detecting fetal HBB carrier status (homozygous 202 unaffected versus heterozygous unaffected). Values were reported with 95% confidence interval.

203

### 204 **Results:**

#### 205 Subject demographics

Seventy-nine pregnant women identified as healthy carriers for, or affected by, a beta hemoglobinopathy at Baylor College of Medicine or UAB were enrolled in this retrospective study. Maternal beta hemoglobinopathy status included HbAS (n = 59), HbAC (n = 13), HbSS (n = 4),

11

and HbCC (n = 1). Additionally, one patient had a whole gene HBB deletion while another was
heterozygous for the beta-plus mutation HBB:c.-79A>G. The mean fetal fraction was 10.7%
(range 1.1% - 23.1%). Gestational ages ranged from 16.4 weeks to collection at delivery.

212

#### 213 sgNIPT accurately detects fetal sickle cell disease

sgNIPT was performed on the 79 subjects. The sgNIPT analysis determines a 'Low Risk', 214 'Decreased Risk', 'High Risk', or 'No Call' classification. The residual risk, i.e. post-test 215 probability, of fetal beta hemoglobinopathy is also calculated. The ground truth of whether the 216 fetus is affected with a beta hemoglobinopathy was obtained by either chart review of the state-217 sponsored newborn screen or genotyping of umbilical cord blood. The sgNIPT analysis correctly 218 219 identified the two newborns who had SCD, demonstrating 100% concordance (Table 1). One of the 'High Risk' sgNIPT cases was a sickle cell anemia affected HbSS newborn whose mother also 220 had sickle cell anemia. The fetal fraction of sgNIPT for this case was 4.1%. The other 'High Risk' 221 222 sgNIPT case was an HbSC newborn whose mother was heterozygous for the HbC (c.19G>A) variant. Both 'High Risk' sgNIPT results returned a residual risk to the fetus of >9 in 10. The vast 223 224 majority of the 'Low Risk' calls had a fetal residual risk of 1 in 20,000; a few of the 'Low Risk' 225 calls had a residual risk as high as 1 in 2,000 (Fig. 1A). There were two out of 79 'No Call' results released via HBB NIPT total for a 'No Call' rate of 2.5%. Both of these 'No Calls' had a relatively 226 227 low fetal fraction (1.2% and 3.8%). Newborn outcomes determined one of these newborns to be 228 unaffected and one affected with SCD. Of note, the affected 'No call' was near the high end of the 229 no call range, with a residual risk of 1 in 13, compared to a prior risk of 1 in 32 (see methods, Fig. 1A). One sample was designated as "decreased risk" because carrier screening indicated that the 230 mother was HbAS, and the sgNIPT test detected that the fetus had inherited an HbC allele from 231

12

the father. Dosage analysis on the maternal HbS allele was performed to determine that the fetus
was likely an unaffected carrier with genotype HbAC, therefore lowering the residual risk from 1
in 2 to 1 in 200.

235

#### 236 sgNIPT accurately determines fetal carrier status for beta hemoglobinopathies

To further demonstrate the ability of sgNIPT to detect fetal beta hemoglobinopathy variants, we next evaluated the ability of sgNIPT to predict the fetal *HBB* genotype. In general, the fetal genotype measurement is technically more challenging than an assessment of the fetal disease risk, because genotyping requires determining whether the fetus inherited 0, 1, or 2 copies of paternal and maternal variants. Classification of the fetal disease inheritance, on the other hand, only requires categorizing the inheritance pattern into either 2 copies or fewer than 2 copies.

The fetal genotype was determined for 68 of the 75 sgNIPT results. The two SCD NIPT 243 no calls were excluded from this analysis. The two beta thalassemia carrier patients were also 244 245 excluded because they were not detectable by the newborn ground truth methodology. As expected from the increased technical challenge, fetal genotyping had a higher no call rate (7 out of 75 246 247 patients) compared to fetal disease risk. Of the remaining 68 patients, sgNIPT genotype results 248 were concordant with ground truth newborn genotype results in all but one sample (Table 2). The strength of the statistical evidence for inheriting 0, 1, or 2 copies of each variant is summarized by 249 250 a fetal genotype score (Figure 1B). Samples with a genotype score above a threshold are classified 251 as heterozygous and below are homozygous; scores close to 0 indicate a relative lack of evidence 252 in either direction. To avoid returning uncertain results, scores that are in the range [-3, +3] were classified as no calls, consistent with evidence thresholds used previously.<sup>17,18</sup> In the only 253 discordant sample, which was close to the no call cutoff, sgNIPT analysis returned a false positive 254

13

255	fetal genotype of HbAS when the newborn genotype was HbAA (Figure 1B). Overall, sgNIPT
256	demonstrated a 100% (90.8% - 100%, 95% CI) sensitivity and 96.4% (81.7% - 99.9%, 95% CI)
257	specificity for detecting whether the fetus is a carrier of a beta hemoglobinopathy.
258	

259 **Discussion/Comments:** 

#### 260 1. Principal Findings

Our NIPT approach<sup>18</sup> for beta hemoglobinopathies was validated in the retrospective cohort study 261 262 reported here. Out of the 79 carrier or affected pregnancies screened, sgNIPT detected two fetuses that were high risk for a beta hemoglobinopathy; this was 100% concordant with the newborn 263 results. Crucially, sgNIPT was able to evaluate the fetal risk even though paternal genotype data 264 was unavailable for all of these subjects. Our ability to discern fetal sickle cell carrier status further 265 validated the accuracy of our approach, since this is a more technically challenging task than 266 determining the fetal SCD status. Overall, there were 28 non-carriers and 38 sickle cell carriers. 267 The sensitivity of detecting fetal carriers of beta hemoglobinopathies 100% (90.8% to 100%, 95% 268 CI), and the specificity was 96.4% (81.7% to 99.9 % CI). 269

270

#### 271 **2.** Clinical Implications

Our data suggest that our sgNIPT can be used to effectively and accurately screen for beta hemoglobinopathies in all pregnancies. Adaptation of this noninvasive, accurate, and affordable single-gene NIPT in the clinics should lead to increased numbers of parents being informed of SCD or beta thalassemia status of their child before birth, even in the 50% of instances when paternal DNA is unavailable.<sup>14</sup> Accurate fetal risk assessment can provide information desired by many patients to aid in making informed decisions regarding prenatal diagnostic testing.

14

Additionally, the personalized information can help prepare parents for delivery and enable cord blood banking of affected newborns, thereby preserving a valuable source of hematopoietic stem cells (HSCs) for rapidly emerging treatment options based on gene therapy. Compared to the current carrier screening workflow, where <42% of affected fetuses may be detected,<sup>14</sup> single-gene NIPT had a 100% sensitivity for detecting fetal hemoglobinopathy in this study.

283

#### 284 **3. Research Implications**

The NIPT for SCD and beta thalassemia that has been clinically validated in this study could enable 285 development of effective cures that can be applied to neonates at early stages of life when gene 286 therapies are typically more effective. As a byproduct of oxygen exchange *in utero*, infants are 287 temporarily protected from the effects of SCD and  $\beta$ -thalassemia mutations for approximately one 288 year while fetal hemoglobin (gamma-hemoglobin) expression remains elevated and adult 289 hemoglobin (beta hemoglobin, location of the mutations) is suppressed.<sup>21</sup> After one year, 290 291 morbidities associated with these diseases begin to accrue and most are irreversible even upon successful stem cell transplantation. NIPT can identify fetuses for whom cord blood should be 292 293 banked for future research and development of treatments based on gene editing of autologous 294 stem cells. It is critical that this readily available source of HSCs not be discarded, as the HSCs of patients with SCD will be invaluable as a potential curative modality, especially early in life. 295 296 Accurate NIPT for SCD and β-thalassemia would allow parents to request cord blood banking of 297 newborns that have these conditions, thereby preserving a valuable source of HSCs for future 298 research and therapies.

299

#### **300 4. Strengths and Limitations**

15

In the present study, we demonstrated the clinical validity of our sgNIPT for SCD and beta 301 thalassemia by analysis of a retrospective cohort of pregnancies and newborn follow-up data. Until 302 303 our approach, NIPT for single-gene recessive disorders had remained technically challenging. We have met this challenge with a highly accurate (even in samples with less than 5% fetal fraction of 304 cfDNA) and resource-efficient test. Our sgNIPT detection of two fetuses with beta 305 hemoglobinopathies was 100% concordant with newborn results. Even though there were only a 306 small number of SCD affected fetuses, our test also correctly determined the sickle cell carrier 307 status of 67 out of 68 fetuses (98.5% concordant with newborn results). This level of accuracy is 308 more suited to clinical use, compared to a previous digital PCR-based single-gene NIPT that 309 reported genotype concordance of only about 80%.<sup>16</sup> A second approach that relies on haplotyping 310 has also been proposed.<sup>22</sup> While accurate, this method requires expensive whole-genome 311 sequencing of both parents and a highly technical assay resulting in high costs and long turn-312 around-time, both of which preclude it from routine clinical use. In contrast, the sgNIPT assay 313 314 presented here does not require paternal DNA, is significantly more cost effective, and can have faster turnaround time. 315

Based on the promising results of this retrospective clinical study, subsequent research is needed to enroll large number of patients in a prospective study to evaluate use of combined carrier screening and reflex sgNIPT for improving clinical care. In the current study, we enrolled pregnant patients identified as healthy carriers or affected mothers for beta hemoglobinopathies. In a future prospective study, establishing the study cohort by enrolling all patients who are undergoing first trimester prenatal screening would be more representative of the intended clinical use case.

322

323 5. Conclusions

324	Our NIPT analysis in a retrospective cohort of 79 pregnant women identified as healthy carriers
325	or affected mothers for SCD or beta thalassemia showed that single-gene NIPT is a highly accurate
326	approach for prenatal detection of these diseases. Combined with the unique workflow of reflex
327	single-gene NIPT for carrier mothers without the need for a paternal sample, this screen allows for
328	an efficient and accurate fetal risk assessment for beta hemoglobinopathies in pregnant women.

# 330 Highlights

331	•	Non-invasive prenatal testing for sickle cell disease and $\beta$ -thalassemia is accurate
332	•	Non-invasive prenatal testing was validated in retrospective cohort studies

• Adaptation of non-invasive prenatal testing can improve clinical care for patients

334

# 336 Acknowledgements

- 337 Research reported in this publication was supported by the National Heart, Lung, and Blood
- Institute of the National Institutes of Health under award number R43HL144322. In the study,
- 339 10% was funded by federal sources, and 90% was funded by BillionToOne. The content is solely
- 340 the responsibility of the authors and does not necessarily represent the official views of the
- 341 National Institutes of Health. We thank Dr. Rong Mao and Dr. Jacqueline Carozza for providing
- 342 editorial support.

343

19

# 345 **References**

- 346 1. Williams TN, Weatherall DJ. World Distribution, Population Genetics, and Health Burden
- 347 of the Hemoglobinopathies. *Cold Spring Harb Perspect Med.* 2012;2(9):a011692.
- 348 doi:10.1101/CSHPERSPECT.A011692
- 2. Sedrak A, Kondamudi NP. Sickle Cell Disease. *StatPearls*. February 2021.
- 350 https://www.ncbi.nlm.nih.gov/books/NBK482384/. Accessed August 4, 2021.
- 351 3. Piel FP, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med. 2017;377(3):302-
- 352 305. doi:10.1056/NEJMC1706325
- 4. The Centers for Disease Control and Prevention. Data & Statistics on Sickle Cell Disease.
- 354 www.cdc.gov. https://www.cdc.gov/ncbddd/sicklecell/data.html. Published 2020.
- Accessed August 4, 2021.
- 356 5. Michlitsch J, Azimi M, Hoppe C, et al. Newborn screening for hemoglobinopathies in
- 357 California. *Pediatr Blood Cancer*. 2009;52(4):486-490. doi:10.1002/PBC.21883
- 358 6. Cao A, Galanello R. Beta-thalassemia. *Genet Med.* 2010;12(2):61-76.
- doi:10.1097/gim.0b013e3181cd68ed
- 360 7. The American College of Obstetricians and Gynecologists. Committee Opinion No. 691:
- 361 Carrier Screening for Genetic Conditions. *Obstet Gynecol*. 2017;129(3):e41-e55.
- 362 doi:10.1097/AOG.000000000001952
- 363 8. Dever DP, Porteus MH. The changing landscape of gene editing in hematopoietic stem
- 364 cells: a step towards Cas9 clinical translation. *Curr Opin Hematol.* 2017;24(6):481-488.
- 365 doi:10.1097/MOH.0000000000385

		20
366	9.	Fitzhugh C, Hsieh MM, Bolan CD, Saenz C, Tisdale JF. Granulocyte colony-stimulating
367		factor (G-CSF) administration in individuals with sickle cell disease: time for a
368		moratorium? Cytotherapy. 2009;11(4):464-471. doi:10.1080/14653240902849788
369	10.	Marktel S, Scaramuzza S, Cicalese M, et al. Intrabone hematopoietic stem cell gene
370		therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia.
371		Nat Med. 2019;25(2):234-241. doi:10.1038/S41591-018-0301-6
372	11.	Ribeil J-A, Hacein-Bey-Abina S, Payen E, et al. Gene Therapy in a Patient with Sickle
373		Cell Disease. N Engl J Med. 2017;376(9):848-855. doi:10.1056/NEJMOA1609677
374	12.	Thompson AA, Walters MC, Kwiatkowski J, et al. Gene Therapy in Patients with
375		Transfusion-Dependent β-Thalassemia. N Engl J Med. 2018;378(16):1479-1493.
376		doi:10.1056/NEJMOA1705342
377	13.	Ghi T, Sotiriadis A, Calda P, et al. ISUOG Practice Guidelines: invasive procedures for
378		prenatal diagnosis. Ultrasound Obstet Gynecol. 2016;48(2):256-268.
379		doi:10.1002/UOG.15945
380	14.	Giles Choates M, Stevens BK, Wagner C, Murphy L, Singletary CN, Wittman AT. It
381		takes two: uptake of carrier screening among male reproductive partners. Prenat Diagn.
382		2020;40(3):311-316. doi:10.1002/PD.5588
383	15.	Norton ME, Jacobsson B, Swamy GK, et al. Cell-free DNA Analysis for Noninvasive
384		Examination of Trisomy. N Engl J Med. 2015;372(17):1589-1597.
385		doi:10.1056/NEJMOA1407349
386	16.	Barrett AN, McDonnell TCR, Chan KCA, Chitty LS. Digital PCR Analysis of Maternal
387		Plasma for Noninvasive Detection of Sickle Cell Anemia. Clin Chem. 2012;58(6):1026-

388 1032. doi:10.1373/CLINCHEM.2011.178939

21

389	17.	Camunas-Soler J, Lee H, Hudgins L, et al. Noninvasive Prenatal	Diagnosis	of Single-
			U	<u> </u>

- Gene Disorders by Use of Droplet Digital PCR. *Clin Chem.* 2018;64(2):336-345.
- doi:10.1373/CLINCHEM.2017.278101
- 18. Tsao DS, Silas S, Landry BP, et al. A novel high-throughput molecular counting method
- 393 with single base-pair resolution enables accurate single-gene NIPT. Sci Rep. 2019;9(1):1-
- 394 14. doi:10.1038/s41598-019-50378-8
- 19. 1000 Genomes Project. Population Genetics for Variant rs334. Ensembl GRCh37 Release
  104.
- 397 https://grch37.ensembl.org/Homo\_sapiens/Variation/Population?db=core;r=11:5247732-
- 398 5248732;v=rs334;vdb=variation;vf=340756472#population\_freq\_AFR. Published 2021.

Accessed August 4, 2021.

- 400 20. Hayden SR, Brown MD. Likelihood Ratio: A Powerful Tool for Incorporating the Results
- 401 of a Diagnostic Test Into Clinical Decisionmaking. *Ann Emerg Med.* 1999;33(5):575-580.

402 doi:10.1016/S0196-0644(99)70346-X

- 403 21. Akinsheye I, Alsultan A, Solovieff N, et al. Fetal hemoglobin in sickle cell anemia. *Blood*.
  404 2011;118(1):19-27. doi:10.1182/BLOOD-2011-03-325258
- 405 22. Hui WWI, Jiang P, Tong YK, et al. Universal Haplotype-Based Noninvasive Prenatal
- 406 Testing for Single Gene Diseases. *Clin Chem.* 2017;63(2):513-524.
- 407 doi:10.1373/CLINCHEM.2016.268375

408





4 Figure 1: Single-gene NIPT accurately determines fetal risk and carrier status (genotype)



СЛ

- 11 genotyping results were concordant with ground truth newborn screen, except for one sample
- 12 that was determined to be AS by NIPT and AA by newborn screen.

# Tables

# Table 1: Concordance between sgNIPT and outcomes for newborns affected with beta hemoglobinopathies

		Newborn outcome		
		Unaffected	Affected	
	Low-risk/ Decreased risk	75	0	
call	High-risk/ Increased risk	0	2	
Tqin	No-call	1	1	

		Newborn outcome				
Normal Traits		Traits		Disease		
		AA	AS	AC	SC	SS
	AA	27	0	0	0	0
	AS	1	31	0	0	0
	AC	0	0	7	0	0
call	SC	0	0	0	1	0
NIPT	SS	0	0	0	0	1

## Table 2: Concordance between sgNIPT and outcomes for newborn HBB genotypes